Abstract: A kit for preparing a radiolabeled liposome is provided, the kit including a liposome suspension and a radionuclide, wherein the liposome suspension includes a conjugate with a structure of [chelator-hydrophilic polymer-lipid]. A method for preparing a radiolabeled liposome using the kit is also disclosed herein, thereby the radiolabeled liposome being produced with the conjugate connected to the surface therein. The advantages of the present disclose such as simple, convenient and without purifying for the produced radiolabeled liposome are thus achieved. Further, the produced radiolabeled liposome has a high specific activity and a high sensitivity and suits for the clinical use.

Abstract: The invention relates to liposome compositions for delivering, for example, therapeutic, diagnostic, and imaging agents to a subject. Methods for preparing and using such liposome compositions are further provided. The compositions and methods of the invention find particular use in treating, diagnosing, and imaging a tumor in a subject.

Abstract: This invention is to manufacture a kit for preparation of nano-targeted liposome drugs in combined chemotherapy and radionuclide therapy. It is a kit consisting of three components: (1) A 10 ml vial A which contains BMEDA, gluconate acetate, SnCl2. (2) A 10 ml vial B which contains DSPC, cholesterol, DSPE-PEG, and Doxorubicin(DXR) (or Daunorubicin, Vinolbine). (3) A 10 ml vial C which contains 188ReO4? (or 186ReO4?) solution. The procedure of using the kit is as follows: (1) Remove the contents of the 188ReO4? (or 186ReO4?) solution from vial C. (2) Inject the 188ReO4? (or 186ReO4?) solution into the vial A, and the mixtures react in appropriate temperature. (3) Remove the contents of the 188Re-BMEDA (or 186Re-BMEDA) solution from vial A. (4) Inject the 188Re-BMEDA (or 186Re-BMEDA) solution into the vial B, and the mixtures react in appropriate temperature. The reconstituted solution in the vial B is applied to combine bimodality radiochemotherapy for treatment of tumor and ascites.

Abstract: The invention discloses one immunoassay for aflatoxin-albumin adducts measurement in serum. In Particular, serum pretreatments including albumin precipitation, resuspension, dialysis, albumin digestion, enzyme precipitation and aflatoxin extraction, centrifugation and resuspension are unnecessary, which is convenient for clinical routine serum testing. The invention also discloses their clinical uses in rapid measurement of the doses of aflatoxin exposure, which is one of risk factors of liver cancer.

Abstract: The invention discloses one radioimmunoassay testing kit and method for detecting aflatoxin-albumin adducts. The radioimmunoassay testing kit combining with competitive inhibition radioimmunometric assay, could be used to quantitate the aflatoxin-albumin adducts in serum. The invention also discloses their clinical uses in rapid mass detection of the doses of aflatoxin exposure, which is one of risk factors of liver cancer.

Abstract: The invention discloses one radioimmunoassay testing kit and method for detecting aflatoxin-albumin adducts. The radioimmunoassay testing kit combining with competitive inhibition radioimmunometric assay, could be used to quantitate the aflatoxin-albumin adducts in serum. The invention also discloses their clinical uses in rapid mass detection of the doses of aflatoxin exposure, which is one of risk factors of liver cancer.

Abstract: This invention is a novel synthesis of BCA-peptides (BCA: bifunctional chelating agents). In this method, the starting material--Fmoc-Thr(ol)-Terephthal-Acetal-Amide Resin is coupled with the various amino acids. The straight peptide-resin of D-Phe-Cys(Trt)-Phe-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(ol)-Terephtha l-Acetal-Amide Resin was obtained. This compound reacted with iodine to give disulfide-containing peptide resin of ##STR1## Cleavage of the peptide from the resin was achieved by TFA. The cleavaged peptide was protected by the reaction of octreotide with di-t-butyldicarbonate. BCA was coupled to the selectively protected octreotide. This product was obtained by reaction of protected BCA-peptides with TFA. The final product was labeled by radioisotope .sup.111 InCl.sub.3 for tumor imaging radiopharmaceuticals.

Abstract: A synergistic extractant combination consisting of di(2-ethylhexyl) phosphoric acid (D2EHPA) and dibutyl butyl phosphonate (DBBP) in kerosene is employed in a two-cycle separation process for the recovery of uranium from wet-process phosphoric acid. The addition of the sulfuric acid and water scrubbing steps for the recycled extractant provides no disadvantages with respect to the comtamination and dilution by the ammonium ion and water to the phosphoric acid and also no precipitation occurs in the second cycle extraction step. The advantages of this process are lower chemical cost, higher product purity and better phase separation in comparison with the previous process.

Abstract: In the process of uranium recovery from wet-process phosphoric acid, post treatment of the raffinate phosphoric acid is very important to prevent damage to the rubber linings of the acid evaporators and to recover the solvent for reuse. A simple and continuous method using an inclined parallel-corrugated-plate separator to remove the organic solvent entrainment from the raffinate phosphoric acid is established herein.